# Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201

> **NCT00362700** · PHASE2 · TERMINATED · sponsor: **Bukwang Pharmaceutical** · enrollment: 33 (—)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Clevudine

## Key facts

- **NCT ID:** NCT00362700
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 33 (—)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362700, "Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00362700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*